A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors

Study Overview

• Status: Completed
• Conditions: Renal Cell Carcinoma; Non Small Cell Lung Cancer; Bladder Cancer; Triple Negative Breast Cancer; Colorectal Cancer Metastatic; GastroEsophageal Cancer; MSI-H
• Intervention / Treatment: Biological: EDP1503; Biological: Pembrolizumab

Detailed Description

This will be a Phase I open-label study which will involve a 2-week monotherapy with EDP1503, following which the patients will be dosed with a combination of EDP1503 and pembrolizumab.

• Study Type: Interventional
• Enrollment (Actual): 69
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Québec, Canada, G1R 2J6
    • CHU de Québec - Université Laval
  • Quebec
    • Montréal, Quebec, Canada, H3T1E2
      • Jewish General Hospital
    • Montréal, Quebec, Canada, H2X 0A9
      • Centre de Recherche du CHUM
• United States
  • Arkansas
    • Rogers, Arkansas, United States, 72758
      • Highlands Oncology Group
  • Florida
    • Sarasota, Florida, United States, 34232
      • Florida Cancer Specialists
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • Stephenson Cancer Center
  • Tennessee
    • Chattanooga, Tennessee, United States, 37404
      • Tennessee Oncology, PLLC
    • Nashville, Tennessee, United States, 37203
      • Tennessee Oncology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Selected Inclusion Criteria:

1. Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors who have had disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment.
2. Have adequate organ function as defined in the clinical protocol. Specimens must be collected within 10 days prior to the start of study treatment.
3. Have provided an archival tumor tissue sample obtained since the most recent prior anticancer regimen or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.
4. Measurable disease by RECIST v1.1 as assessed by the local site investigator/radiologist. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
5. Metastatic disease not suitable for upfront curative-intent surgery.
6. Progressive disease on previous line of therapy per treating investigator (additional specific criteria for cohort C).
7. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
8. Additional tumor-specific inclusion criteria

Selected Exclusion Criteria:

1. Has received prior radiotherapy within 2 weeks of start of study treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
2. Treatment with investigational therapy within 28 days prior to initiation of study treatment.
3. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE).

4. Has received prior systemic anti-cancer therapy within 28 days or 5 half-lives, whichever is shorter prior to treatment.

   Note: Patients must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Patients with ≤Grade 2 neuropathy may be eligible.

   Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.

5. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

   1. Unstable angina or acute myocardial infarction ≤ 3 months prior to C1D1;
   2. Clinically significant heart disease (e.g., symptomatic congestive heart failure [e.g., >NYHA Class 2]; uncontrolled arrhythmia, or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen).
6. Uncontrolled active severe systemic infection requiring parenteral antibiotics within 1 week, and systemic antivirals or antifungals within two weeks prior to C1D1.
7. Patients with active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
8. Patients with severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.

9. Prior malignancies:

   1. Patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (i.e. cervix, breast) may enroll irrespective of the time of diagnosis.
   2. Patients with a known additional malignancy that is progressing or has required active treatment within the past which may interfere with the interpretation of the study. Cancer treated with curative intent < 5 years previously will not be allowed unless approved by the Sponsor. Cancer treated with curative intent > 5 years previously and without evidence of recurrence will be allowed.
10. Patients with a diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.
11. Patients with uncontrolled vomiting or dirrahea that could interfere with the GI exposure to EDP1503.
12. Patients who are transfusion dependent should be discussed with the Medical Monitor
13. Patients unwilling to comply with the protocol including required biopsies and sample collections required to measure disease.
14. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
15. Has received a live vaccine within 30 days of planned C1D1. Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed. Intranasal influenza vaccines (e.g FluMist) are live attenuated vaccines and are not allowed.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort A; Cohort A includes patients with microsatellite stable (MSS) colorectal cancer (CRC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.	Biological: EDP1503; 4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10^10 colony-forming units (CFU); Biological: Pembrolizumab; 200 mg given by intravenous (IV) infusion once every 3 weeks; Other Names: Keytruda
Experimental: Cohort B; Cohort B includes patients with Triple Negative Breast Cancer (TNBC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.	Biological: EDP1503; 4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10^10 colony-forming units (CFU); Biological: Pembrolizumab; 200 mg given by intravenous (IV) infusion once every 3 weeks; Other Names: Keytruda
Experimental: Cohort C; Cohort C includes patients with non-small-cell lung cancer (NSCLC), bladder cancer; gastroesophageal (GE) cancer, any microsatellite unstable, or renal cell carcinoma (RCC) who are relapsed to prior PD-1/L1 therapy. Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.	Biological: EDP1503; 4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10^10 colony-forming units (CFU); Biological: Pembrolizumab; 200 mg given by intravenous (IV) infusion once every 3 weeks; Other Names: Keytruda

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability of EDP1503 alone and in combination with pembrolizumab as assessed per CTCAE v5.0	Number of participants with EPD1503 related adverse events as assessed per CTCAE v5.0	2 years
Safety and tolerability of EDP1503 alone and in combination with pembrolizumab	Safety and tolerability of EDP1503 alone and in combination with pembrolizumab assessed via clinical laboratory evaluations	2 years
Evidence of anti-tumor activity of EDP1503 based on ORR	To determine preliminary evidence of anti-tumor activity of EDP1503 in patients	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival	Progression Free Survival	2 years
Overall Survival	Overall Survival	2 years

Collaborators and Investigators

• Sponsor: Evelo Biosciences, Inc.
• Collaborators: Merck Sharp & Dohme LLC; SCRI Development Innovations, LLC

Study record dates

Study Major Dates

• Study Start (Actual): December 19, 2018
• Primary Completion (Actual): June 30, 2021
• Study Completion (Actual): October 31, 2021

Study Registration Dates

• First Submitted: December 12, 2018
• First Submitted That Met QC Criteria: December 12, 2018
• First Posted (Actual): December 14, 2018

Study Record Updates

• Last Update Posted (Actual): March 24, 2023
• Last Update Submitted That Met QC Criteria: March 22, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Skin Diseases; Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Breast Diseases; Kidney Neoplasms; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Carcinoma, Renal Cell; Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Triple Negative Breast Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Pembrolizumab
• Other Study ID Numbers: EDP1503-101; KEYNOTE-939 (Other Identifier: Merck Sharp & Dohme Corp.)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No